Skip to main content
Smart Investors Daily
CH

NASDAQ · CHSCL

CHS Inc.

Consumer Defensive · Agricultural Farm Products

$24.58

Down-$0.33 (-1.34%)

Updated Oct 30, 2026, 8:46 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
315.88M
P/E ratio
0
Dividend yield
9.54%
52-week range
$24.15 – $25.95
Volume
33.09K
Avg. volume
25.4K

Price performance · CHSCL

CHSCL price history

1M range · 0 trading sessions · Daily adjusted prices

CHSCL does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CHSCL news

The latest Smart Investors Daily articles mentioning CHSCL.

CHSCL research

Overview

Company profile and research snapshot.

Company profile

CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

seekingalpha.com · Oct 1, 2025

Coherus Oncology: Five Readouts Or More Possible In 2026

Coherus Oncology's Loqtorzi has resumed growth in earnest, with Q2 2025 net revenues of $10M. The company could report readouts from its drugs in three indications in H1 2026: casdozokitug in hepatocellular carcinoma, CHS-114 in gastric cancer, and CHS-114 in head and neck cancer. There could be further readouts from CHS-114 in 2026 in esophageal squamous cell carcinoma and colorectal cancer.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.